News

The company has also delivered the GMP grade product to Neogenix in preparation for Phase I/II clinical trials planned for the first half of 2009. NPC-1C is a

The study has demonstrated that repeat intravenous treatment with pegylated-rHuPH20 enzyme (PEGPH20) as a single agent in the PC3 mouse model resulted in approximately 70% (p=0.001) tumor growth

The reduction in workforce will extend the company’s existing cash resources to fund operations until around the end of 2009. The measures are expected to be implemented with

In Australia, Meridian has signed an agreement with Sydney-based Immuno. For Argentina, Meridian has signed with Scott Pharma, a healthcare distributor. This decision is consistent with Meridian’s stated

The Phase III multi-center, randomized, double-blind, placebo-controlled trial in approximately 850 migraine sufferers is evaluating the safety and efficacy of MAP0004 as a potential acute treatment for migraine.

In this role, Dr Vaishnaw will be responsible for continued leadership of the company’s clinical activities; he will continue to report to John Maraganore, Alnylam’s CEO. Dr Vaishnaw

This agreement is in addition to the prior one announced in July 2007 to develop a novel stent system for coronary artery disease, which is now in clinical

The RFD submission is part of a process with the FDA for determining which agency component will have primary jurisdiction for a drug, device or biological product. The

As BaroFold’s new president and CEO, Dr Freytag brings more than 25 years of experience in the biotechnology and pharmaceutical industries. Most recently, Dr Freytag served as chairman